Protocol No. CL010_168: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Safety and Efficacy of CCX168 (Avacopan) in Patients with Anti-Neutrophil Cytoplasmic Antibody (ANCA)- Associated Vasculitis Treated Concomitantly with
|Effective start/end date||11/1/17 → 12/31/22|
- ChemoCentryx, Inc.
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.